Health · Healthcare & Policy · 6 hrs ago
Canada clears myLoop insulin system for use in Type 1 diabetes pregnancies
Health Canada cleared myLoop for use during pregnancy in people with Type 1 diabetes on Oct.
30.
The system combines a glucose monitor, software that calculates insulin needs and a device that delivers insulin.
It acts like an artificial pancreas, helping people manage a condition in which the pancreas no longer makes insulin.
Pregnancy can make managing Type 1 diabetes more stressful and increase the risks involved.
The clearance may make the system easier to prescribe and could help expand public funding or insurance coverage, experts say.
One component is targeted for commercial availability in late 2026 or early 2027, according to mylife Diabetes Care, the company behind myLoop.
Health Canada cleared myLoop for use during pregnancy by people with Type 1 diabetes, according to the company behind the system.
The clearance was announced on Oct. 30 and makes myLoop the first system in Canada cleared for this use.
Automated insulin delivery systems monitor glucose, calculate insulin needs and deliver insulin.
Experts say regulatory approvals can help providers prescribe these systems and may expand public funding or insurance coverage.
A myLoop glucose monitor component is targeted to become commercially available in late 2026 or early 2027, according to the company.
- Who
- mylife Diabetes Care says its myLoop system received clearance. The system is intended for people with Type 1 diabetes who are pregnant.
- What
- Health Canada cleared myLoop for use during pregnancy. The clearance covers all three system components and their integration.
- When
- Oct. 30. The article was published on Nov. 9, 2026.
- Where
- Canada.
- Why
- The clearance allows the system to be used for Type 1 diabetes management during pregnancy. Regulatory approvals may also help providers prescribe the systems and expand coverage.
This story does not have two clearly opposing sides.
A different system, Control-IQ+, became the first to receive U.S. Food and Drug Administration clearance for managing Type 1 diabetes in pregnancy.
myLoop received Health Canada clearance for use during pregnancy by people with Type 1 diabetes, according to its maker.
mylife Diabetes Care said it is targeting this period for its glucose monitor component to become commercially available.
- System
- myLoop
- Clearance date
- Oct. 30
- Cleared use
- Type 1 diabetes during pregnancy
- Company
- mylife Diabetes Care
- Canadian prevalence
- Around 300,000 people have Type 1 diabetes in Canada
What people are saying
We have come a very long way in how we manage glucose during pregnancy
We’ve finally gotten to a place with our technology where we can make a really meaningful impact on a reduction in those diabetes complications. It’s remarkably changed the face of diabetes management.
I have alarms in the night because of my Type 1 diabetes